抗高血压药物类别和非叶片内脑内出血后的功能结果
Mohamed Ridha1, James F Burke1, Padmini Sekar2
1Department of Neurology, The Ohio State University, Columbus.
JAMA network open
|February 3, 2025
概括
在非叶片内脑出血 (ICH) 后,启动血管激素转化酶抑制剂 (ACEI) 或血管激素受体抑制剂 (ARB) 与更好的功能结果有关. 这表明,在高血压动脉病症中,除了血压控制之外,还有一种特定的益处.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 高血压是非叶片内脑出血 (ICH) 的主要原因.
- 抗高血压剂对大脑微血管结构有多种影响.
- 特定抗高血压药类对ICH后功能结果的影响尚不清楚.
研究的目的:
- 调查在住院期间开始服用抗高血压药物类别与非叶膜性ICH患者的90天功能结果之间的关联.
主要方法:
- 一项队列研究利用了来自脑内出血的种族/种族变异研究 (ERICH) 的数据.
- 分析包括了具有可用的结局数据的非叶膜ICH的幸存者.
- 混合效应逻辑回归被用来评估有利的功能结果的几率 (修改的兰金得分0-2在90天),调整为共变量.
主要成果:
- 在1079名非叶膜ICH参与者中,启动ACE抑制剂或ARB与更高的90天良好功能结局的几率有关 (调整后OR,1.49;P=.01).
- 对于其他抗高血压类 (通道阻断剂,β-阻断剂, thiazide 利尿剂) 没有发现显著的关联.
- ACEI/ARB与良好的结果之间的关联是由大脑小血管疾病的放射特征介导的.
结论:
- 在非叶膜性ICH之后启动ACE抑制剂或ARB与90天后功能结果的改善有关.
- 这表明在管理高血压动脉病变方面,有潜在的药物类特定益处.
- 在部ICH病例中没有观察到这种关联.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
01:16Antihypertensive Drugs: Action of Diuretics
613
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
613
01:28Antihypertensive Drugs: Types of β-Blockers
570
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
570
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
404
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
404
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131